University of Pittsburgh, Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease, Pulmonary, Allergy, and Critical Care Medicine , Pittsburgh, PA , USA
Expert Opin Biol Ther. 2013 Oct;13(10):1429-40. doi: 10.1517/14712598.2013.833603. Epub 2013 Aug 28.
Many lung diseases have high morbidity and mortality rates and there are no cures or treatments apart from mechanical ventilation or transplantation. Cell-based therapies are currently an area of intense research, and many groups are working to translate successful in vitro results into treatments that are safe for patients.
This review discusses several types of stem and progenitor cells that have been proven likely candidates for cell therapies, as well as their applications so far in specific acute and chronic lung diseases, focusing on their mechanisms of action and how best they can be directed toward clinical aims.
The research on cell therapies for the lung, particularly regarding mesenchymal stem cells (MSCs), is promising, but there is still much uncertainty surrounding the mechanisms of MSC action and the factors relevant to clinical applications such as the optimal timing of dosage. Future studies will focus on the microenvironment of the stem cells, including the role of microRNAs and extracellular vesicles.
许多肺部疾病的发病率和死亡率都很高,除了机械通气或移植之外,没有治愈方法或治疗方法。基于细胞的疗法目前是一个研究热点,许多研究小组正在努力将体外的成功结果转化为对患者安全的治疗方法。
本文讨论了几种已被证明可能适用于细胞疗法的干细胞和祖细胞,以及它们迄今为止在特定急性和慢性肺部疾病中的应用,重点介绍了它们的作用机制以及如何最好地将它们指向临床目标。
肺部细胞疗法的研究,特别是间充质干细胞(MSCs)的研究很有前景,但关于 MSC 作用的机制以及与临床应用相关的因素(如剂量的最佳时间)仍然存在很大的不确定性。未来的研究将集中在干细胞的微环境上,包括 microRNAs 和细胞外囊泡的作用。